Literature DB >> 19269958

Adipokines as novel biomarkers in paediatric systemic lupus erythematosus.

Marjon Al1, Lawrence Ng, Pascal Tyrrell, Joanne Bargman, Timothy Bradley, Earl Silverman.   

Abstract

OBJECTIVES: Patients with SLE are at risk for premature atherosclerosis and metabolic syndrome. Cytokines produced by adipocytes, adipokines, are important in glucose/lipid metabolism and the development of atherosclerosis. The objectives of this study were to evaluate leptin, adiponectin and ghrelin concentrations in paediatric SLE (pSLE) and to correlate these concentrations with measures of disease activity, serum lipid concentrations, measures of insulin resistance and serum homocysteine concentrations.
METHODS: Two hundred and eight samples from 105 patients with pSLE and 77 samples from 77 healthy paediatric controls were evaluated by ELISA to measure leptin, adiopnectin and ghrelin. Students' t-test was used for analysis. Concentrations of adipokines were correlated with disease activity, serum lipids, insulin resistance and homocysteine.
RESULTS: Overall 35 SLE patients (34%) had an abnormally elevated leptin level. The only significant correlation of leptin concentrations was with homocysteine concentrations but not disease activity, prednisone dose, lipids or insulin resistance. There was no difference in the mean adiponectin concentrations between the control and patient groups and none of the patient samples were below the normal lower limit while seven were elevated. There was a significant correlation of adiponectin concentrations with prednisone dose, lipid concentrations and insulin resistance but not with disease activity or homocysteine. Elevated ghrelin concentrations were found in 20% of the pSLE patients. The only correlation of ghrelin concentrations was with homocysteine.
CONCLUSIONS: Adipokines are novel biomarkers in pSLE. They may represent cardiovascular risk and are not just surrogate markers for disease activity, therapy or serum lipids. Their correlation with atherosclerosis needs to be explored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269958     DOI: 10.1093/rheumatology/kep030

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  18 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 2.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

3.  Resistin as a potential marker of renal disease in lupus nephritis.

Authors:  J Hutcheson; Y Ye; J Han; C Arriens; R Saxena; Q-Z Li; C Mohan; T Wu
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

4.  A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Brian J Skaggs; Jennifer M Grossman; Lori Sahakian; John Fitzgerald; Weng Kee Wong; Elaine V Lourenco; Nagesh Ragavendra; Christina Charles-Schoeman; Alan Gorn; George A Karpouzas; Mihaela B Taylor; Karol E Watson; Michael H Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheumatol       Date:  2014-01       Impact factor: 10.995

Review 5.  Biomarkers for childhood-onset systemic lupus erythematosus.

Authors:  Khalid M Abulaban; Hermine I Brunner
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 6.  Accelerated atherosclerosis in patients with SLE--mechanisms and management.

Authors:  Brian J Skaggs; Bevra H Hahn; Maureen McMahon
Journal:  Nat Rev Rheumatol       Date:  2012-02-14       Impact factor: 20.543

Review 7.  Emerging role of adipokines in systemic lupus erythematosus.

Authors:  Hong-Miao Li; Tian-Ping Zhang; Rui-Xue Leng; Xiang-Pei Li; Xiao-Mei Li; Hai-Rong Liu; Dong-Qing Ye; Hai-Feng Pan
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

Review 8.  Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases.

Authors:  Morena Scotece; Javier Conde; Rodolfo Gómez; Verónica López; Jesús Pino; Antonio González; Francisca Lago; Juan J Gómez-Reino; Oreste Gualillo
Journal:  Mediators Inflamm       Date:  2012-07-15       Impact factor: 4.711

Review 9.  Cardiovascular risk in pediatric-onset rheumatological diseases.

Authors:  Julie Barsalou; Timothy J Bradley; Earl D Silverman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

10.  Ghrelin and adipokines as circulating markers of disease activity in patients with Takayasu arteritis.

Authors:  Hatice Yilmaz; Vedat Gerdan; Didem Kozaci; Dilek Solmaz; Servet Akar; Gercek Can; Aytac Gulcu; Yigit Goktay; Ismail Sari; Merih Birlik; Nurullah Akkoc; Fatos Onen
Journal:  Arthritis Res Ther       Date:  2012-12-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.